FDA Small Business Waivers: How Startups Can Reduce Regulatory Costs Without Slowing Development
- Jul 13
- 4 min read
For emerging biotech and life sciences companies, every dollar matters. Between research and development, clinical trials, manufacturing, and regulatory activities, bringing a new therapy to market requires significant investment. Fortunately, the FDA offers programs that can help qualifying companies reduce some of these financial barriers through small business fee waivers and reductions.
Understanding these programs early can help startups preserve capital while maintaining momentum toward critical regulatory milestones. So before you submit your application, it can be very worth researching them and determining eligibility. This blog will get you started. Of note: Any Small Business Waiver agreements will need to be included in the application.
What Are FDA Small Business Waivers?
The FDA administers several user fee programs that support the review of drugs, biologics, medical devices, and other regulated products. These fees help fund timely application reviews but can be substantial for small companies.
To encourage innovation, Congress authorized certain fee waivers, exemptions, and reductions for businesses that meet specific eligibility requirements. Depending on the product type and submission, qualifying companies may receive:
Waivers of application fees
Reduced user fees
Exemptions from certain annual fees
Discounts for first-time marketing applications
These programs can save companies hundreds of thousands—or even millions—of dollars during product development.
Which FDA Programs Offer Small Business Benefits?
Small business provisions vary depending on the FDA user fee program.
Prescription Drug User Fee Act (PDUFA)
Under PDUFA, eligible companies may qualify for a waiver of the application fee for their first human drug application if they meet FDA's small business criteria.
Eligibility generally depends on:
Number of employees
Company ownership and affiliates
Whether the company has previously submitted a qualifying application
Because eligibility requirements are specific, companies should begin preparing documentation well before their planned NDA or BLA submission.
Medical Device User Fee Amendments (MDUFA)
Medical device companies may qualify for significant fee reductions under MDUFA.
Benefits may include:
Reduced 510(k) fees
Reduced De Novo fees
Reduced PMA fees
Lower establishment registration fees in certain situations
Companies must apply annually for Small Business Determination before receiving reduced fees.
Generic Drug User Fee Amendments (GDUFA)
Certain generic drug manufacturers may qualify for reduced facility fees or other financial considerations depending on their business structure and participation in the program.
Biosimilar User Fee Act (BsUFA)
Biosimilar sponsors should carefully review available fee provisions, as some fees may be adjusted or waived depending on development stage and applicable statutory provisions.
Why Startups Should Plan Early
One common misconception is that companies can request fee reductions at the time of submission.
In reality, many FDA programs require sponsors to:
Submit eligibility documentation in advance
Receive FDA determination before submission
Meet annual deadlines
Maintain supporting corporate documentation
Waiting until an application is ready can delay submissions or prevent companies from receiving available financial benefits.
Documentation Is Critical
Obtaining a small business determination often requires supporting documentation such as:
Corporate ownership information
Affiliate relationships
Employee counts
Financial certifications
Organizational structure documentation
Maintaining accurate corporate records makes the application process significantly smoother.
Regulatory Operations Plays an Important Role
Although small business waivers are often viewed as a financial or administrative task, they also require careful regulatory planning.
Regulatory operations teams can help organizations:
Track eligibility timelines
Coordinate supporting documentation
Ensure user fee planning aligns with submission schedules
Verify application requirements before filing
Reduce the risk of submission delays caused by administrative issues
Integrating fee planning into the overall regulatory strategy helps organizations avoid last-minute surprises.
Best Practices for Emerging Biotech Companies
As your development program advances, consider these best practices:
Evaluate eligibility as early as possible.
Understand which FDA user fee program applies to your product.
Build waiver and fee planning into your regulatory timeline.
Coordinate across finance, legal, regulatory affairs, and regulatory operations.
Monitor FDA guidance for program updates and annual fee changes.
The Bottom Line
FDA small business waivers and fee reductions can provide meaningful financial relief for emerging biotechnology and life sciences companies. However, these benefits require advance planning, accurate documentation, and a clear understanding of FDA eligibility requirements.
For startups operating with limited resources, incorporating user fee planning into your regulatory strategy can help preserve capital, reduce administrative delays, and keep development programs on schedule. And that starts with understanding what applies to you and tracking Agency timelines. For example: as of July 13th, the FDA reports that for small business requests:
The application window for FY 2026 MDUFA Small Business Requests (SBR) for medical devices closes on August 1, 2026, at 4:00 PM ET. Applications submitted after this time will not be accepted for FY 2026.
The application window for FY 2027 MDUFA Small Business Requests (SBR) opens on August 1, 2026, at 4:01 PM ET. Applications submitted before this time will not be accepted for FY 2027.
At The Sugar Water Operations Team, we encourage sponsors to think beyond submission readiness, and that includes ways to save your investor dollars. Successful regulatory programs begin with strategic planning—including understanding available FDA fee relief programs and integrating them into a comprehensive regulatory operations roadmap.
Contact SWOT at info@sugarwaterops.com for additional questions regarding ways to create and/or use a Submission Content Planner to get the most out of it.
Additional resources can be found at:
Guidance for Industry User Fee Waivers, Reductions, and Refunds for Drug and Biological Products - 2011 - https://www.fda.gov/media/72340/download
